JP2005503146A - 変形性関節症の治療に用いるための細胞組成物と、その製造方法 - Google Patents
変形性関節症の治療に用いるための細胞組成物と、その製造方法 Download PDFInfo
- Publication number
- JP2005503146A JP2005503146A JP2003520762A JP2003520762A JP2005503146A JP 2005503146 A JP2005503146 A JP 2005503146A JP 2003520762 A JP2003520762 A JP 2003520762A JP 2003520762 A JP2003520762 A JP 2003520762A JP 2005503146 A JP2005503146 A JP 2005503146A
- Authority
- JP
- Japan
- Prior art keywords
- cell composition
- cells
- mesenchymal
- synovial fluid
- mesenchymal cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 201000008482 osteoarthritis Diseases 0.000 title abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 244
- 238000000034 method Methods 0.000 claims abstract description 87
- 210000001179 synovial fluid Anatomy 0.000 claims abstract description 80
- 230000007547 defect Effects 0.000 claims abstract description 34
- 210000001519 tissue Anatomy 0.000 claims abstract description 26
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 24
- 210000000845 cartilage Anatomy 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 26
- 238000004113 cell culture Methods 0.000 claims description 13
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 230000004069 differentiation Effects 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 7
- 241001653121 Glenoides Species 0.000 claims description 6
- 238000010353 genetic engineering Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000005482 chemotactic factor Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000035605 chemotaxis Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 6
- 208000012659 Joint disease Diseases 0.000 abstract description 4
- 230000003349 osteoarthritic effect Effects 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000037231 joint health Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 description 1
- 208000002804 Osteochondritis Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- -1 PDGF Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002450 kidney nerve cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1317—Chondrocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10139783A DE10139783C1 (de) | 2001-08-14 | 2001-08-14 | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung |
| PCT/EP2002/009080 WO2003015803A1 (de) | 2001-08-14 | 2002-08-13 | Zellzusammensetzungen zur behandlung von osteoarthrose, sowie verfahren zu deren herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503146A true JP2005503146A (ja) | 2005-02-03 |
| JP2005503146A5 JP2005503146A5 (enExample) | 2006-01-05 |
Family
ID=7695336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003520762A Pending JP2005503146A (ja) | 2001-08-14 | 2002-08-13 | 変形性関節症の治療に用いるための細胞組成物と、その製造方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040241144A1 (enExample) |
| EP (1) | EP1418927A1 (enExample) |
| JP (1) | JP2005503146A (enExample) |
| DE (1) | DE10139783C1 (enExample) |
| WO (1) | WO2003015803A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506937A (ja) * | 2013-02-04 | 2016-03-07 | セルラー バイオメディスン グループ（上海）リミテッドＣｅｌｌｕｌａｒ Ｂｉｏｍｅｄｉｃｉｎｅ Ｇｒｏｕｐ （Ｓｈａｎｇｈａｉ） Ｌｔｄ． | 変形性関節症の予防または治療における異系間質血管層細胞および異系間葉前駆細胞の使用 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10333901A1 (de) * | 2003-07-21 | 2005-03-10 | Transtissue Technologies Gmbh | Verwendung von Chemokinen zur Rekrutierung von humanen mesenchymalen Vorläuferzellen zur Regeneration von Gelenkdefekten |
| KR20070085288A (ko) * | 2004-09-24 | 2007-08-27 | 안지오블라스트 시스템스 인코퍼레이티드 | 간엽 전구세포의 증식 및/또는 생존성 증강 방법 |
| DE102005030614B4 (de) * | 2005-06-30 | 2014-05-08 | Biotissue Ag | Zellfreies Transplantat, dessen Verwendung, Verfahren zu dessen Herstellung, dabei hergestellte Matrix mit Gel und Verfahren zur Herstellung dieser Matrix mit Gel |
| KR101378874B1 (ko) | 2005-10-13 | 2014-03-27 | 안트로제네시스 코포레이션 | 태반 줄기세포를 이용한 면역 조절 |
| PT2471907T (pt) | 2005-12-29 | 2019-01-28 | Celularity Inc | Populações de células estaminais placentárias |
| JP2009521931A (ja) | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法 |
| NZ568618A (en) * | 2005-12-29 | 2011-10-28 | Anthrogenesis Corp | Co-culture of placental stem cells and stem cells from a second source |
| EP2422800A3 (en) | 2006-03-07 | 2013-03-06 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| DE102006047346A1 (de) | 2006-10-06 | 2008-04-10 | Transtissue Technologies Gmbh | Matrix-Gel-Transplantat ohne Zellen |
| ME01562B (me) | 2007-02-12 | 2014-09-20 | Anthrogenesis Corp | Liječenje protuupalnih bolesti putem matičnih stanica posteljice |
| CN101688177A (zh) | 2007-02-12 | 2010-03-31 | 人类起源公司 | 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群 |
| AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| KR20190122891A (ko) | 2008-08-20 | 2019-10-30 | 안트로제네시스 코포레이션 | 단리된 태반 세포를 사용한 뇌졸중 치료 |
| KR20240052847A (ko) | 2008-08-20 | 2024-04-23 | 셀룰래리티 인코포레이티드 | 개선된 세포 조성물 및 그의 제조 방법 |
| HRP20130812T1 (en) | 2008-08-22 | 2013-09-30 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| JP5869342B2 (ja) | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
| CA2787992A1 (en) | 2010-01-26 | 2011-08-04 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
| CA2795518C (en) | 2010-04-07 | 2020-03-24 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
| MX2012011543A (es) | 2010-04-08 | 2013-05-06 | Anthrogenesis Corp | Tratamiento de sarcoidosis empleando celulas madre placentarias. |
| EP3358007A1 (en) | 2010-07-13 | 2018-08-08 | Celularity, Inc. | Methods of generating natural killer cells |
| EP2658557A1 (en) | 2010-12-31 | 2013-11-06 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
| DK2714059T3 (en) | 2011-06-01 | 2019-01-21 | Celularity Inc | TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS |
| CA2850977C (en) * | 2011-10-13 | 2020-10-13 | Kci Licensing, Inc. | Stimulation of cartilage formation using reduced pressure treatment |
| CN115137753A (zh) | 2013-02-05 | 2022-10-04 | 细胞结构公司 | 来自胎盘的自然杀伤细胞 |
| US20210047621A1 (en) | 2018-03-12 | 2021-02-18 | Universidade Do Porto | Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells |
| CN108815187A (zh) * | 2018-07-20 | 2018-11-16 | 深圳市第二人民医院 | 一种包含人关节液外泌体的制剂及其使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| WO1998051317A1 (en) * | 1997-05-13 | 1998-11-19 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration using human mesenchymal stem cells |
| US6835377B2 (en) * | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
| US20020005205A1 (en) * | 2000-04-25 | 2002-01-17 | Barry Francis P. | Joint repair using mesenchymal stem cells |
| US6800298B1 (en) * | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
-
2001
- 2001-08-14 DE DE10139783A patent/DE10139783C1/de not_active Expired - Fee Related
-
2002
- 2002-08-13 US US10/486,956 patent/US20040241144A1/en not_active Abandoned
- 2002-08-13 EP EP02764845A patent/EP1418927A1/de not_active Withdrawn
- 2002-08-13 WO PCT/EP2002/009080 patent/WO2003015803A1/de not_active Ceased
- 2002-08-13 JP JP2003520762A patent/JP2005503146A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506937A (ja) * | 2013-02-04 | 2016-03-07 | セルラー バイオメディスン グループ（上海）リミテッドＣｅｌｌｕｌａｒ Ｂｉｏｍｅｄｉｃｉｎｅ Ｇｒｏｕｐ （Ｓｈａｎｇｈａｉ） Ｌｔｄ． | 変形性関節症の予防または治療における異系間質血管層細胞および異系間葉前駆細胞の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040241144A1 (en) | 2004-12-02 |
| EP1418927A1 (de) | 2004-05-19 |
| DE10139783C1 (de) | 2003-04-17 |
| WO2003015803A1 (de) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005503146A (ja) | 変形性関節症の治療に用いるための細胞組成物と、その製造方法 | |
| Saeed et al. | Mesenchymal stem cells (MSCs) as skeletal therapeutics–an update | |
| Caplan | Mesenchymal stem cells: cell–based reconstructive therapy in orthopedics | |
| US7078232B2 (en) | Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof | |
| CN107223153B (zh) | 包含源于正分化成软骨细胞之干细胞的外排体的用于软骨细胞分化诱导或软骨组织再生的组合物 | |
| KR20080043809A (ko) | 척추 유합에서의 지방 조직-유래 스트로마 세포의 사용 | |
| CN102026546A (zh) | 软骨修复的合成物和方法 | |
| JP2005503146A5 (enExample) | ||
| JP7350344B2 (ja) | ヒト誘導万能幹細胞から軟骨細胞のペレットを製造する方法およびその用途 | |
| Gottfried et al. | Mesenchymal stem cell and gene therapies for spinal fusion | |
| AU2013206755B2 (en) | Activating adipose-derived stem cells for transplantation | |
| KR102091442B1 (ko) | 건 또는 인대 손상 치유를 위한 자가 및 동종의 지방유래 중간엽줄기세포 조성물 및 이의 제조방법 | |
| Tsujii et al. | Next generation approaches for cartilage repair and joint preservation | |
| US9434923B2 (en) | Preparation of parental cell bank from foetal tissue | |
| KR20150138700A (ko) | 건 또는 인대 손상 치유를 위한 자가 및 동종의 지방유래 중간엽줄기세포 조성물 및 이의 제조방법 | |
| KR20110032433A (ko) | 세포이식술을 위한 혼합세포복합체인 세포스페로이드의 제조방법 및 이의 이용방법 | |
| Schwarz et al. | Characterization of adipose-derived equine and canine mesenchymal stem cells after incubation in agarose-hydrogel | |
| KR20140049772A (ko) | 근골격계 질환의 예방 또는 치료용 조성물 | |
| RU2461621C1 (ru) | Способ стимуляции формирования фиброзно-хрящевого регенерата костной мозоли у млекопитающих | |
| CN101247814A (zh) | 用于骨折愈合的半固体混合纤维蛋白成骨细胞成分及其制备方法 | |
| US20190328933A1 (en) | Composite-interfacing biomaterial accelerant substrate | |
| CN111849876A (zh) | 诱导培养基及用于治疗关节炎的成软骨细胞的制备方法 | |
| CN111481572A (zh) | 用于治愈肌腱或韧带损伤的自体及同种的脂肪来源间充质干细胞组合物及其的制备方法 | |
| CN117337185A (zh) | 包含缺端胶原和真皮鞘杯(dsc)细胞的组合物、用于将毛发再生的试剂盒、制造用于将毛发再生的组合物的方法和将毛发再生的方法 | |
| HK1198179B (en) | Preparation of parental cell bank from foetal tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050812 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081009 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081017 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090305 |